A randomized open-label trial of the efficacy of ranolazine in patients with type 2 diabetic dyslipidemia

Abstract

Ranolazine is an oral antianginal drug that has been proven effective in reducing HbA1c and fasting plasma glucose levels in patients with type 2 diabetes in numerous studies. The current investigation was intended to study the effect of ranolazine in treating type 2 diabetic dyslipidemia by studying its effect on beta-cell function, insulin sensitivity, and lipid profiles in addition to glycemic parameters in patients with diabetic dyslipidemia. A randomized, open-label study was conducted in 82 patients with type 2 diabetic dyslipidemia for 24 weeks. The subjects were included according to study criteria and randomized into two groups. One group received standard treatment and the other group received ranolazine along with standard treatment. At baseline, 12th and 24th weeks, the glycemic and lipid parameters, body mass index (BMI), homeostasis model assessment of beta-cell function (HOMA2-%B), homeostasis model assessment of peripheral insulin sensitivity (HOMA2-%S) were measured. Significant difference was observed in the mean change of FPG (P = 0.002), PPG (P = 0.01), HbA1C (P = 0.002), Fasting insulin (P = 0.05), HOMA-IR (P = 0.02), HOMA2-%B (P = 0.01), HOMA2-%S (P = 0.01), TG (P = 0.002), LDL (P = 0.01), TC (P = 0.002) after 24 weeks of ranolazine treatment when compared to standard treatment. The addition of ranolazine to the standard treatment in the patients with type 2 diabetic dyslipidemia was effective in controlling glycemic and lipid parameters. The study results also indicated that 24 weeks of ranolazine treatment increased insulin sensitivity and beta-cell function. • Ranolazine showed significant efficacy by reducing glycemic parameters in diabetic dyslipidemia patients. • β – cell function and insulin sensitivity increased in ranolazine treatment group. • Significant reduction in the triglycerides was observed in the ranolazine treatment when compared to standard.